BOSTON, May 24, 2019 — King & Spalding has received the 2019 Novartis Global Outside Counsel award for “Excellence in Litigation Strategy.”
Frankfurt-based FDA and Life Sciences partner Ulf Grundman received the award on behalf of the firm at a meeting in Boston on May 19th.
Novartis recognized the firm for developing a tool to support Novartis’s efforts to protect patients’ health and raise/maintain market shares of the branded pharmaceutical industries versus parallel traders in the European Union (EU) by combining trademark laws and the new EU Falsified Medicines Directive.
In addition, the firm helped Novartis to win more than a dozen cases including preliminary injunctions versus parallel traders in less than a year without losing a case.
King & Spalding’s FDA and Life Sciences team guides companies through all aspects of U.S. and EU regulatory compliance, unfair competition and trademark challenges. The practice works through every issue at every stage of a product’s life cycle.
About King & Spalding
Celebrating more than 130 years of service, King & Spalding is an international law firm that represents a broad array of clients, including half of the Fortune Global 100, with 1,100 lawyers in 20 offices in the United States, Europe, the Middle East and Asia. The firm has handled matters in over 160 countries on six continents and is consistently recognized for the results it obtains, uncompromising commitment to quality, and dedication to understanding the business and culture of its clients. More information is available at www.kslaw.com.